Posterior capsular opacification: a problem reduced but not yet eradicated - PubMed (original) (raw)

Review

Posterior capsular opacification: a problem reduced but not yet eradicated

Niranjan Awasthi et al. Arch Ophthalmol. 2009 Apr.

Abstract

Posterior capsular opacification (PCO) is the most frequent complication of cataract surgery. Advances in surgical techniques, intraocular lens materials, and designs have reduced the PCO rate, but it is still a significant problem. The only effective treatment for PCO, Nd:YAG laser capsulotomy carries vision-related complications and risks and puts a significant financial burden on the health care system. This review contains current knowledge about the mechanisms of PCO development. Posterior capsular opacification is caused mainly by remnant lens epithelial cell proliferation and migration, epithelial-mesenchymal transition, collagen deposition, and lens fiber generation. All of these processes are influenced by cytokines, growth factors, and extracellular matrix proteins. We also describe advances and improvements in surgical techniques, intraocular lens materials, and the designs and use of therapeutic agents leading to safe, effective, and less expensive strategies to eradicate PCO.

PubMed Disclaimer

Similar articles

• Posterior capsule opacification: a review of the aetiopathogenesis, experimental and clinical studies and factors for prevention.
  Pandey SK, Apple DJ, Werner L, Maloof AJ, Milverton EJ. Pandey SK, et al. Indian J Ophthalmol. 2004 Jun;52(2):99-112. Indian J Ophthalmol. 2004. PMID: 15283214 Review.
• Update on fixation of rigid and foldable posterior chamber intraocular lenses. Part II: Choosing the correct haptic fixation and intraocular lens design to help eradicate posterior capsule opacification.
  Ram J, Apple DJ, Peng Q, Visessook N, Auffarth GU, Schoderbek RJ Jr, Ready EL. Ram J, et al. Ophthalmology. 1999 May;106(5):891-900. doi: 10.1016/S0161-6420(99)00506-0. Ophthalmology. 1999. PMID: 10328386
• [Posterior capsule opacification: incidence and pathogenesis].
  Zemaitiene R. Zemaitiene R. Medicina (Kaunas). 2003;39(9):830-7. Medicina (Kaunas). 2003. PMID: 14515044 Review. Lithuanian.
• Optic edge design as long-term factor for posterior capsular opacification rates.
  Kohnen T, Fabian E, Gerl R, Hunold W, Hütz W, Strobel J, Hoyer H, Mester U. Kohnen T, et al. Ophthalmology. 2008 Aug;115(8):1308-14, 1314.e1-3. doi: 10.1016/j.ophtha.2008.01.002. Epub 2008 Mar 5. Ophthalmology. 2008. PMID: 18321585 Clinical Trial.
• Posterior capsule opacification.
  Dewey S. Dewey S. Curr Opin Ophthalmol. 2006 Feb;17(1):45-53. doi: 10.1097/01.icu.0000193074.24746.e6. Curr Opin Ophthalmol. 2006. PMID: 16436924 Review.

Cited by

• MiR-22-3p inhibits fibrotic cataract through inactivation of HDAC6 and increase of α-tubulin acetylation.
  Wang X, Wang L, Sun Y, Chen B, Xiong L, Chen J, Huang M, Wu J, Tan X, Zheng Y, Huang S, Liu Y. Wang X, et al. Cell Prolif. 2020 Nov;53(11):e12911. doi: 10.1111/cpr.12911. Epub 2020 Sep 28. Cell Prolif. 2020. PMID: 32985730 Free PMC article.
• An overview of the influence and design of biomaterial of the intraocular implant of the posterior capsule opacification.
  Nanu RV, Ungureanu E, Instrate SL, Vrapciu A, Cozubas R, Carstocea L, Voinea LM, Ciuluvica R. Nanu RV, et al. Rom J Ophthalmol. 2018 Jul-Sep;62(3):188-193. Rom J Ophthalmol. 2018. PMID: 30505987 Free PMC article. Review.
• Risk factors for the occurrence of visual-threatening posterior capsule opacification.
  Chen HC, Lee CY, Sun CC, Huang JY, Lin HY, Yang SF. Chen HC, et al. J Transl Med. 2019 Jun 20;17(1):209. doi: 10.1186/s12967-019-1956-6. J Transl Med. 2019. PMID: 31221170 Free PMC article.
• EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model.
  Wertheimer C, Siedlecki J, Kook D, Mayer WJ, Wolf A, Klingenstein A, Kampik A, Eibl-Lindner K. Wertheimer C, et al. Graefes Arch Clin Exp Ophthalmol. 2015 Mar;253(3):409-17. doi: 10.1007/s00417-014-2875-0. Epub 2014 Dec 5. Graefes Arch Clin Exp Ophthalmol. 2015. PMID: 25471020
• Study of Intraocular Pressure following Neodynium Yttrium Aluminium Garnet Laser Capsulotomy with the Use of Brimonidine: A Descriptive Cross-sectional Study.
  Manandhar LD, Gurung N, Shrestha K, Bhattarai B, Godar M, Shrestha R. Manandhar LD, et al. JNMA J Nepal Med Assoc. 2021 Jan 31;59(233):15-18. doi: 10.31729/jnma.5130. JNMA J Nepal Med Assoc. 2021. PMID: 34508462 Free PMC article.

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information